Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Chinook Therapeutics Inc ADRO


Primary Symbol: KDNY

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.


NDAQ:KDNY - Post by User

Post by AviseAnalyticson Sep 01, 2021 7:08am
143 Views
Post# 33793107

5 BIOTECH STOCKS INSIDERS ARE BUYING!

5 BIOTECH STOCKS INSIDERS ARE BUYING!
$KRON $EYEN $PRLD $NBSE $KDNY

Insider selling or buying cannot be the sole indicator for investing in a stock, but it would be wise to make a note of the buying and selling activities to gauge a company’s prospects or the lack thereof. While insiders buying or selling the Company’s stock could provide investors with a general idea about the direction it is headed, a thorough understanding of its fundamentals, recent news and analyst estimates should be taken into consideration while making an investment decision.
 
We take a look at five companies that have witnessed insider buying in the past year.

[url=https://www.aviseanalytics.com/5-biotech-stoc...re-buying/ ]Learn more[/url]

https://www.aviseanalytics.com/5-biotech-stoc...re-buying/
 

<< Previous
Bullboard Posts